Table 3 Differences in oncologist- and patient-assessed performance status (PS) scores in relation to disease stage, type and sex of patient

From: Performance status score: do patients and their oncologists agree?

 

Doctor-assessed PS score compared to patient assessed PS score

Group/subgroup ( n)

Under-rated (D<P) n (%)

Agree (D=P) n (%)

Over-rated (D>P) n (%)

All patients (101)

27 (27)

51 (50)

23 (23)

Females (29)

3 (10)

16 (55)

10 (35)

Males (72)

24 (33)

35 (49)

13 (18)

NSCLC

 Stage unknown (1)

1 (100)

–

–

 Stage I (18)

5 (28)

9 (50)

4 (22)

 Stage II (4)

1 (25)

3 (75)

–

 Stage III (39)

11 (28)

19 (49)

9 (23)

 Stage IV (19)

6 (32)

6 (32)

7 (36)

SCLC

 Limited (11)

1 (9)

8 (73)

2 (18)

 Extensive (6)

1 (17)

4 (66)

1 (17)

  1. Stage of NSCLC was not associated with PS score, whether assessed by patient or oncologist (P=0.18). Although there was no statistical difference in PS scores between males and females (P=0.37), oncologists generally gave lower PS scores to female patients (P=0.04, marginally significant). D=doctor-assessed PS score; P=patient-assessed PS score; NSCLC=non-small-cell lung cancer; SCLC=small-cell lung cancer.
Back to article page